![ema glp-1 vision loss recommendation 2025 Ozempic Lawsuit [2026 Update] GLP-1 medications and eye problem](https://www.torhoermanlaw.com/wp-content/uploads/2024/09/Ozempic-Vision-Loss-Lawsuit-768x432.jpg)
ema glp-1 vision loss recommendation 2025 Ozempic Lawsuit [2026 Update] GLP-1 medications and eye problem
Description
After propensity scores overlap weighting, 13,965 pairs of GLP1-RA versus DPP4i initiators (cohort entry: 20062022
![ema glp-1 vision loss recommendation 2025 Ozempic Lawsuit [2026 Update] GLP-1 medications and eye problem](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1381644686846824)
Bre Teamer chats with Dr
![ema glp-1 vision loss recommendation 2025 Ozempic Lawsuit [2026 Update] GLP-1 medications and eye problem](https://www.qps.com/wp-content/uploads/2025/06/Vision-Changes-Linked-to-GLP-1-Drugs_horizontal.png)
Sequence: EGTFTSDVSSYLEGQAAKEFIAWLVKGR(NH2)
![ema glp-1 vision loss recommendation 2025 Ozempic Lawsuit [2026 Update] GLP-1 medications and eye problem](https://s3-ap-southeast-2.amazonaws.com/media.mieducation.production/logos/qiHJahBlhgTjHhENHx4sG2hLoYm6NtYVo3Qs6RV0.jpg)
A comprehensive literature search was conducted across the PubMed, Embase, and Google Scholar databases for peer-reviewed articles published from inception through June 15, 2026, focusing on the landmark SURPASS, SURMOUNT, and SUMMIT trial programs, relevant cardiorenal post hoc analyses, emerging body recomposition trials, and real-world cohort-switching protocols
![ema glp-1 vision loss recommendation 2025 Ozempic Lawsuit [2026 Update] GLP-1 medications and eye problem](https://www.ema.europa.eu/sites/default/files/styles/ema_smp_opengraph/public/2025-09/2025-09_Falsified%20GLP1%20statement-3-_WEB_square_0.png.webp?itok=w64bbD_A)
